How to access Doptelet from India — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient with chronic immune thrombocytopenia (ITP) who has had insufficient response to previous therapy, or an Indian patient with thrombocytopenia secondary to chronic liver disease who is scheduled for an elective procedure, may receive a prescription for Doptelet (avatrombopag) from their treating haematologist or hepatologist. Doptelet is FDA-approved for chronic ITP in adults with insufficient response to previous therapy, and for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure. It is manufactured by Sobi. Doptelet is a small-molecule thrombopoietin (TPO) receptor agonist taken orally, and it does not require the meal-timing-independent and food-interaction complexities that characterise some other oral TPO-RAs. In India, Doptelet may not yet be broadly registered, which is why your physician may be navigating a named-patient import pathway with you.
This guide explains the legal pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
Note on context: This guide replaces a prior planned entry for Adakveo (crizanlizumab) × India. Adakveo's commercial status has shifted in multiple international markets following post-marketing data, and Reserve Meds does not currently prioritise Adakveo as a first-cohort pair. Doptelet is substituted as a commercially stable hematology pair at comparable rank.
The clinical situation
Doptelet is an oral tablet. For chronic ITP, dosing is initiated at 20 mg once daily with food and titrated based on platelet response (target platelet count typically ≥50 × 10⁹/L). For chronic liver disease thrombocytopenia prior to a procedure, dosing is weight-independent at 40–60 mg daily for 5 days starting 10–13 days before the procedure. Doptelet should be taken with food for optimal absorption. Your treating physician confirms diagnosis, baseline labs (platelets, liver function, prior-therapy history for ITP), and the dosing plan per FDA labeling.
Is Doptelet legally importable into India?
Yes — through the Central Drugs Standard Control Organization (CDSCO) named-patient / personal-use import framework. The pathway allows an Indian-licensed physician (or the patient directly, with physician prescription) to request import of a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent registered alternative fits, (c) the physician takes clinical responsibility, and (d) the imported quantity is proportionate to a defined treatment period.
For avatrombopag specifically, the application is routine — an oral tablet with standard room-temperature handling and no REMS or controlled-substance complexity.
How the pathway works, step by step
- Consultation with your treating physician. ITP or chronic-liver-disease-associated thrombocytopenia diagnosis, prior therapy history (for ITP), baseline labs, and clinical rationale for Doptelet.
- CDSCO named-patient / personal-use application. Your physician or the importing pharmacy files the application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner.
- Shipment. Doptelet ships at controlled room temperature; no cold-chain is required.
- Arrival and dosing start. The treating physician initiates titrated dosing (for ITP) or the 5-day procedural course (for chronic liver disease thrombocytopenia).
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming chronic ITP with insufficient response to prior therapy, or chronic liver disease thrombocytopenia prior to procedure, baseline labs, and Doptelet as indicated treatment
- Verification of Indian medical licence
- Patient identifier
- Planned dosing schedule and projected tablet count
Reserve Meds provides a physician documentation kit that bundles the templates CDSCO reviewers expect to see.
Costs and timing
Doptelet's US cash-pay reference price sits in a broad indicative range — the per-course cost for chronic liver disease thrombocytopenia (5-day procedural use) typically falls in the USD 10,000–15,000 range in US list pricing. For chronic ITP, ongoing dosing varies with titration but falls in the annualised USD 60,000–120,000 range. International logistics, CDSCO documentation, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.
Indicative timing — not guaranteed — for the first dispensed supply after cohort intake opens is approximately 14–21 days from the moment a complete application is submitted. For procedural dosing in chronic liver disease, the 10–13-day pre-procedure window must be factored into application timing.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Doptelet specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for CDSCO review.
- Logistics. Controlled-room-temperature shipment.
- Concierge case lead. A named point of contact.
What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating physician.
Frequently asked
Is this legal in India? Yes, when executed through the CDSCO named-patient / personal-use framework with appropriate documentation.
How does Doptelet compare with eltrombopag or romiplostim? All three are TPO-receptor agonists. Eltrombopag (Promacta/Revolade) is oral but has strict dietary-cation restrictions and requires fasting. Romiplostim (Nplate) is a weekly subcutaneous injection. Doptelet is oral, taken with food, without the cation-restriction complexity of eltrombopag — a practical advantage for many patients. Your physician chooses based on clinical profile and practical factors.
Why am I seeing this guide labelled as a substitute for Adakveo? Adakveo (crizanlizumab) was the originally planned pair for this slot. Its commercial status has shifted in multiple international markets following post-marketing data, and we did not want to build first-cohort capacity around an uncertain product. Doptelet replaces Adakveo as a commercially stable hematology pair at comparable rank.
Will private insurance cover this? Cash-pay is the default. Some Indian private insurers reimburse named-patient ITP therapy on escalated review; we supply documentation but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Doptelet coordination in India.
Add me to the Doptelet waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.